Group 1 - The core point of the news is that Genting New Year (01952) has announced a subscription for 15.8462 million American Depositary Shares (ADS) of I-Mab at a price of $1.95 per ADS, totaling approximately $30.9 million [1][2] - Following the subscription, Genting New Year will hold a total of 15.8462 million ADS and 6.0786 million ordinary shares, representing about 16.1% of I-Mab's total issued share capital after the subscription [1] - I-Mab is a global biotechnology company focused on developing precision immuno-oncology drugs for cancer treatment, with three clinical-stage pipeline products [1] Group 2 - The board believes that the subscription confirms I-Mab's unique capabilities in clinical translation, particularly in the U.S., and complements Genting New Year's strong influence in Asia [2] - The collaboration is expected to create synergies between I-Mab's differentiated 4-1BB technology platform and bispecific antibody development pipeline, enhancing existing investments in mRNA cancer vaccines [2]

Core Viewpoint - Clouding New Horizon (01952) has announced a subscription for 15.8462 million American Depositary Shares (ADS) of I-Mab at a price of $1.95 per ADS, totaling approximately $30.9 million, which will result in a 16.1% ownership stake in I-Mab post-transaction [1][2] Group 1 - The subscription price for each ADS is $1.95, equivalent to approximately 15.3 HKD per ADS, with a total transaction value of $30.9 million (approximately 243 million HKD) [1] - After the completion of the subscription, the company will hold a total of 15.8462 million ADS and 6.0786 million ordinary shares of I-Mab, representing about 16.1% of I-Mab's total issued share capital post-transaction [1] - I-Mab is a global biotechnology company focused on developing precision immuno-oncology drugs for cancer treatment, with three clinical-stage pipeline products [1] Group 2 - The board believes that the subscription will confirm I-Mab's unique capabilities in clinical translation, particularly in the U.S., and will complement the company's strong influence in Asia [2] - The collaboration is expected to create synergies between I-Mab's differentiated 4-1BB technology platform and bispecific antibody development pipeline, enhancing the company's existing investments in mRNA cancer vaccines [2]

Core Insights - Genting Yong's strategic investment in I-Mab amounts to $30.9 million, equivalent to approximately HKD 242.6 million, making it the largest shareholder with a 16.1% stake [1] - This investment marks a significant step in Genting Yong's strategic positioning in the next-generation tumor immunotherapy sector [1] I-Mab's Core Technology and Pipeline Products - I-Mab is a global biotechnology company listed on NASDAQ under the ticker "IMAB," focusing on precision tumor immunotherapy [3] - The company has three clinical pipeline products: Givastomig (Claudin18.2x4-1BB bispecific antibody), Ragistomig (PD-L1x4-1BB bispecific antibody), and Uliledlimab (CD73 antibody) [3] - Recent clinical data from I-Mab indicates an objective response rate of 83% for Givastomig in a Phase 1b dose-escalation study for first-line gastric cancer treatment [3] Strategic Synergy and Global Layout Value - Genting Yong's CEO stated that the investment enhances the company's global strategy in next-generation tumor immunotherapy pipelines [4] - Genting Yong has developed proprietary AI+mRNA and autologous CAR-T platforms, focusing on mRNA therapeutic vaccines and autologous CAR-T therapies [4] - The collaboration between Genting Yong and I-Mab is expected to create a matrix of next-generation tumor immunotherapy products, providing innovative solutions for major treatment areas [4] - The investment leverages I-Mab's clinical development capabilities in the U.S. and complements Genting Yong's strong presence in the Asian market, potentially enhancing the value of core self-developed pipeline products in both the U.S. and China [4]

Group 1 - InnoCare (02577.HK) has partnered with NVIDIA to promote the large-scale implementation of the 800 VDC power architecture in AI data centers, which is designed for efficient power supply in megawatt-level computing infrastructure [1] - The 800 VDC system offers significant advantages over traditional 54V systems in terms of efficiency, thermal loss, and reliability, enabling a 100-1000 times increase in AI computing power [1] - The company's third-generation GaN devices provide a comprehensive power solution from 800V input to GPU terminals, covering a voltage range from 15V to 1200V [1] Group 2 - China Ruyi (00136.HK) received a strategic investment of HKD 3.9 billion from Wuji Capital to accelerate business expansion and acquisition plans [2] - LEPU Biopharma-B (02157.HK) has authorized T-cell connector technology with an upfront payment of USD 10 million and potential milestone payments of up to USD 850 million [2] - Sinopec Engineering (02386.HK) signed a front-end engineering design (FEED) contract for a large green hydrogen project in Yanbu, Saudi Arabia [2] Group 3 - Geely Automobile (00175.HK) reported total vehicle sales of 237,700 units in July, a year-on-year increase of 58% [3] - Great Wall Motors (02333.HK) achieved approximately 104,372 vehicle sales in July, reflecting a year-on-year growth of 14.34% [3] - NIO-SW (09866.HK) delivered 21,017 vehicles in July [3]

Core Viewpoint - Genting Yongyao is making a strategic investment of $30.9 million in I-Mab, acquiring approximately 16.1% of the company's shares, thus becoming its largest shareholder. This investment aims to enhance the development of next-generation tumor immunotherapy pipelines globally [1][2][3]. Group 1: Investment Details - Genting Yongyao will invest $30.9 million (approximately HKD 242.6 million) in I-Mab, which will result in a total ownership of about 16.1% of I-Mab's shares [1][2]. - The investment will be made through the purchase of 15,846,154 American Depositary Shares (ADSs) at a price of $1.95 per share, contributing to a total fundraising of approximately $65 million by I-Mab [4][5]. - The investment will be classified as a non-current asset under the "Investments" section on Genting Yongyao's balance sheet, with subsequent fair value changes reflected in other comprehensive income [4]. Group 2: Clinical Development and Product Pipeline - I-Mab has recently presented promising results for Givastomig (Claudin 18.2 x 4-1BB bispecific antibody) at the 2025 ESMO GI conference, showing an objective response rate (ORR) of 83% in a phase 1b dose-escalation study for first-line gastric cancer treatment [1][5]. - I-Mab's differentiated 4-1BB receptor-targeting platform and bispecific antibody pipeline complement Genting Yongyao's AI+mRNA platform and autologous CAR-T platform, creating a new generation of tumor immunotherapy product matrix [1][3]. - The collaboration is expected to leverage both companies' strengths in clinical development and business expansion, particularly I-Mab's capabilities in the U.S. and Genting Yongyao's advantages in Asia [4].

Group 1 - The core point of the news is that CloudTop New Horizon (云顶新耀) announced an investment of $30.9 million in I-Mab, making it the largest shareholder with approximately 16.1% ownership after the transaction [2][3] - I-Mab is a global biotechnology company based in the United States, listed on NASDAQ, focusing on the development of precision immunotherapy drugs for cancer treatment [2] - I-Mab currently has three clinical development pipeline products, including two bispecific antibodies and one CD73 antibody, with a reported objective response rate (ORR) of 83% in a recent clinical trial for gastric cancer [2] Group 2 - CloudTop New Horizon's CEO stated that the strategic direction of the company aligns well with I-Mab's differentiated 4-1BB platform and bispecific antibody pipeline, which can create a new generation of tumor immunotherapy product matrix [3] - The investment is based on I-Mab's next-generation tumor immune product pipeline and its clinical development capabilities in the U.S., which complement CloudTop's strong presence in the Asian market [3] - The collaboration is expected to leverage both companies' expertise in clinical development and business expansion in China and globally, providing more breakthrough treatment options for cancer patients [3]

Group 1 - Company Gindalbie Metals announced the acquisition of 15.84 million American Depositary Shares (ADS) of I-Mab at a price of $1.95 per ADS, totaling approximately $30.9 million [1] - Following the acquisition, the company will hold a total of 15.84 million ADS and 6.08 million ordinary shares, representing about 16.1% of I-Mab's total issued share capital post-transaction [1] - The company focuses on innovative drug and vaccine research and development, with a strategic pipeline of promising clinical-stage products aimed at addressing unmet medical needs globally [1] Group 2 - I-Mab is a global biotechnology company headquartered in the United States, specializing in precision immuno-oncology drugs for cancer treatment [2] - I-Mab has three clinical-stage pipeline products, including Givastomig, Ragistomig, and Uliledlimab, which are designed to target specific cancer markers [2] - The board believes that the acquisition will enhance I-Mab's unique capabilities in clinical translation, particularly in the U.S., and complement the company's existing investments in mRNA cancer vaccines [2]

Group 1 - Company Gindalbie Metals Limited announced the subscription of 15.8462 million American Depositary Shares (ADS) of I-Mab at a price of $1.95 per ADS, totaling approximately $30.9 million [1] - After the subscription, the company will hold a total of 15.8462 million ADS and 6.0786 million ordinary shares, representing about 16.1% of I-Mab's total issued share capital post-transaction [1] - The company focuses on innovative drug and vaccine research and development, with a strategic pipeline of promising clinical-stage products and aims to address unmet medical needs globally [1] Group 2 - I-Mab is a global biotechnology company headquartered in the United States, specializing in precision immuno-oncology drugs for cancer treatment [2] - I-Mab has three clinical-stage pipeline products, including Givastomig, Ragistomig, and Uliledlimab, showcasing its unique capabilities in clinical translation [2] - The subscription is expected to create complementary and synergistic effects between I-Mab's strengths in the U.S. and the company's influence in the Asia-Pacific region, particularly in the area of mRNA cancer vaccines [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴該 等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：1952） Everest Medicines Limited 雲 頂 新 耀 有 限 公 司 自願性公告 本公告由雲頂新耀有限公司（「本公司」）自願作出。 本 公 司 董 事（「 董 事 」）會（「 董 事 會 」）宣 佈 ， 於 2025 年 8 月 1 日 ， 本 公 司 認 購 I -Mab （「 I -M a b 」）（ 一 間 於 納 斯 達 克 全 球 市 場 上 市 之 公 司 ， 股 份 代 號 為「 IM AB 」）之 15,846,154股美國預託股份（「ADS」）（ 每十(10)股ADS相當於二十三(23)股普通股 ） （「認購事項」），每股ADS為1.95美元（ 相當於約每股ADS 15.3港元 ）。認購事項之 總代價為30.9百萬美元（ 相當於約242.6百萬港元 ）。認購事項完成後，本公司將合 共持有15,846,154股ADS ...

Group 1 - The company completed a placement and subscription agreement on July 30, 2025, successfully placing a total of 22,561,000 shares at a price of HKD 69.70 per share [1] - The company issued the subscribed shares on August 1, 2025, after all conditions of the subscription were met [1] Group 2 - The net proceeds from the subscription amount to approximately HKD 1,553.39 million [2] - The company plans to allocate the net proceeds as follows: 50% (approximately HKD 776.69 million) for global R&D of pipeline products, 40% (approximately HKD 621.36 million) for ongoing commercialization efforts, and 10% (approximately HKD 155.34 million) for working capital and general administrative purposes [2]